A Clinical Trial of TQH3906 Capsules in Healthy Volunteers - Trial NCT06230588
Access comprehensive clinical trial information for NCT06230588 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 76 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 1
Feb 02, 2024
Oct 01, 2024
Primary Outcome
Adverse events (AE),Serious Adverse Events (SAE),Treatment-emergent adverse events (TEAEs)
Summary
This study was divided into three parts: single and multiple dosing and food effect study,
 which were designed to evaluate the safety and tolerability of TQH3906 capsules administered
 in single or multiple dose escalation in healthy adult subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06230588
Non-Device Trial